| (Values in U.S. Thousands) | Dec, 2015 | Dec, 2014 | Dec, 2013 | Dec, 2012 | Dec, 2011 |
| Sales | 0 | 60 | 30 | 10 | 450 |
| Sales Growth | -100.00% | +100.00% | +200.00% | -97.78% | unch |
| Net Income | -22,200 | -14,960 | -19,070 | -12,330 | -10,030 |
| Net Income Growth | -48.40% | +21.55% | -54.66% | -22.93% | unch |
Echo Therapeutics (ECTE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Echo Therapeutics, Inc., a medical device and specialty pharmaceutical company, develops a non-invasive and wireless transdermal continuous glucose monitoring system for people with diabetes and for use in hospital critical care units in the United States. Its Symphony transdermal continuous glucose monitoring System is a non-invasive, wireless, designed to provide reliable, on-demand blood glucose data conveniently, continuously and cost-effectively. The company is based in Franklin, Massachusetts.
Fiscal Year End Date: 12/31